UK markets closed

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
31.91+1.79 (+5.94%)
At close: 04:00PM EST
32.50 +0.59 (+1.85%)
After hours: 05:08PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.71B
Enterprise value 1.29B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)185.61
Price/book (mrq)3.91
Enterprise value/revenue 158.90
Enterprise value/EBITDA -23.08

Trading information

Stock price history

Beta (5Y monthly) 2.72
52-week change 377.87%
S&P500 52-week change 322.74%
52-week high 357.20
52-week low 315.37
50-day moving average 339.43
200-day moving average 339.25

Share statistics

Avg vol (3-month) 3460.85k
Avg vol (10-day) 3591.64k
Shares outstanding 546.66M
Implied shares outstanding 6N/A
Float 839.61M
% held by insiders 14.53%
% held by institutions 194.62%
Shares short (30 Dec 2021) 44.77M
Short ratio (30 Dec 2021) 49.14
Short % of float (30 Dec 2021) 410.28%
Short % of shares outstanding (30 Dec 2021) 410.22%
Shares short (prior month 29 Nov 2021) 44.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 310 Feb 2019
Ex-dividend date 4N/A
Last split factor 21:15
Last split date 310 Feb 2019

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)-726.07%

Management effectiveness

Return on assets (ttm)-10.27%
Return on equity (ttm)-21.68%

Income statement

Revenue (ttm)8.1M
Revenue per share (ttm)0.20
Quarterly revenue growth (yoy)-77.10%
Gross profit (ttm)-35.12M
EBITDA -55.78M
Net income avi to common (ttm)-72.26M
Diluted EPS (ttm)-1.76
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)423.09M
Total cash per share (mrq)9.07
Total debt (mrq)3.08M
Total debt/equity (mrq)0.70
Current ratio (mrq)30.09
Book value per share (mrq)9.36

Cash flow statement

Operating cash flow (ttm)-51.6M
Levered free cash flow (ttm)-26.05M